In line with these findings, zoledronic acid is a potent Kir6.1/2-Sur2A/B blocker targeting either the Kirs or Sur2 subunits, and a low-affinity blocker of the pancreatic Kir6.2-Sur1 channel (Maqoud et al., 2021; Scala et al., 2021) showed low hypoglycemia risk and low risk for pancreatic cancer within the KATP channel blockers. Here, KCNJ11 is linked to familial pancreatic carcinoma.